Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

J Shiao; K M Thomas; A S Rahimi; R Rao; Jingsheng Yan; Xian-Jin Xie; M DaSilva; A Spangler; M Leitch; R Wooldridge; A Rivers; D Farr; B Haley; D W Nathan Kim

doi:10.1007/s10549-016-4081-8

Back

Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

Journal article

Peer reviewed

Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

J Shiao, K M Thomas, A S Rahimi, R Rao, Jingsheng Yan, Xian-Jin Xie, M DaSilva, A Spangler, M Leitch, R Wooldridge, …

Breast cancer research and treatment, Vol.161(3), pp.463-471

02/2017

DOI: 10.1007/s10549-016-4081-8

PMID: 28005245

View Online

Abstract

The objective is to define the therapeutic role of antiplatelet agents in a triple-negative breast cancer (TNBC) population. We performed retrospective analysis using the UTSW TNBC registry containing data from 222 Stage II-III TNBC patients treated between 1998 and 2016. Univariate analysis and multivariable logistic regression models were constructed to identify factors associated with disease-free survival (DFS), distant metastases rate (DMR), and overall survival outcomes. Antiplatelet drug use was determined by review of electronic medical records. A total of 65 patients used antiplatelet (AP) agents, and 157 patients did not use AP agents. Median follow-up for AP and non-AP groups was 41.3 and 40.9 months, respectively. There was an improvement in the AP group compared with the control group in 5-year DFS (80.4% at 5 years compared with 62.3% in the control group, p = 0.04) and 5-year DMR (8.8 vs. 31.9%, p = 0.007). In multivariate analysis, AP use was found to be significantly associated with improvements in DFS and DMR. We illustrate that antiplatelet agent use improves DMR and DFS among a stage II and III TNBC population despite our short follow-up evaluation. Longer follow-up evaluation will be required to determine additional outcome advantage for antiplatelet agent use. Our findings support consideration of investigation of antiplatelet therapy as an adjunctive therapy for TNBC at high risk for disease recurrence.

Humans

Middle Aged

Kaplan-Meier Estimate

Treatment Outcome

Combined Modality Therapy

Triple Negative Breast Neoplasms - mortality

Breast Neoplasms

Triple Negative Breast Neoplasms - drug therapy

Aspirin - administration & dosage

Neoplasm Metastasis

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Triple Negative Breast Neoplasms - diagnosis

Platelet Aggregation Inhibitors - administration & dosage

Aged, 80 and over

Adult

Female

Aged

Aspirin - therapeutic use

Neoplasm Staging

Platelet Aggregation Inhibitors - therapeutic use

Details

Title: Subtitle: Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients
Creators: J Shiao - Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA
K M Thomas - Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA
A S Rahimi - Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA
R Rao - Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Jingsheng Yan - Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
Xian-Jin Xie - Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
M DaSilva - Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
A Spangler - Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA
M Leitch - Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
R Wooldridge - Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
A Rivers - Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
D Farr - Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
B Haley - Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
D W Nathan Kim - Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390-9183, USA. Nathan.kim@utsouthwestern.edu
Resource Type: Journal article
Publication Details: Breast cancer research and treatment, Vol.161(3), pp.463-471
Publisher: Netherlands
DOI: 10.1007/s10549-016-4081-8
PMID: 28005245
ISSN: 0167-6806
eISSN: 1573-7217
Language: English
Date published: 02/2017
Academic Unit: Preventive and Community Dentistry; Biostatistics; Dental Research
Record Identifier: 9983917683202771

Metrics

38 Record Views

34 Times Cited - Web of Science

See more details